title: Analysis of rat natural killer cytotoxic factor (NKCF): mechanism of action and relationship to other cytotoxic/cytostatic factors.
abstract: Natural killer cytotoxic factor (NKCF) has been proposed as one of the factors that mediates lysis induced by natural killer (NK) cells. Recently, an excellent source of NKCF has been found to be the rat large granular lymphocyte (LGL) tumor (RNK) cell line. In this study, the kinetics of lysis of the NK-sensitive, tumor target YAC-1 by the RNK-NKCF was analyzed and found to parallel that seen with NK cell-mediated killing. RNK-NKCF was also capable of killing the NK-resistant target cell, MBL-2, over a longer time period. This study utilized monoclonal antibodies (mAbs) prepared against granule protein, previously termed "anti-NKCF mAbs." These mAbs established the nature of RNK-NKCF as compared to other known cytotoxic factors in combination with studies that show that RNK-NKCF causes both 51Cr release and nuclear degradation. Antibody inhibition experiments have verified that RNK-NKCF is unique from tumor necrosis factor (TNF), leukoregulin, or complement. Anti-NKCF mAbs were capable, however, of neutralizing the RNK cell granule activity against YAC-1 tumor target cells. Based on these results, the ability of anti-NKCF mAbs to neutralize the cytolytic function of pore-forming protein (PFP), a component of these granules, was analyzed. In these experiments, the antibodies were found to inhibit the hemolytic activity of granules. Interestingly, the antibodies were effective in inhibiting the activity of unbound granule proteins as well as those bound to sheep red blood cell (SRBC) targets. Further studies to examine the target lysis requirements demonstrated that in contrast to PFP, the RNK-NKCF was able to lyse the tumor target in the absence of calcium. In addition, treatment of targets with RNA and protein synthesis inhibitors indicated that the mechanism of lysis of NKCF is quite unique from other defined cytotoxic moieties.
authors.affiliation: Laboratory of Experimental Immunology, NCI-FCRDC, Frederick, Maryland 21702-1201.
authors.forename: R T
authors.initials: RT
authors.lastname: Winkler-Pickett
authors.forename: H A
authors.initials: HA
authors.lastname: Young
authors.forename: A
authors.initials: A
authors.lastname: Kuta
authors.forename: J R
authors.initials: JR
authors.lastname: Ortaldo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D002118:Calcium / Q000502:physiology; D003602:Cytotoxicity, Immunologic; D004247:DNA / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D055646:Killer Factors, Yeast; D008222:Lymphokines / Q000494:pharmacology*; D008562:Membrane Glycoproteins; D008565:Membrane Proteins / Q000494:pharmacology; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D011506:Proteins / Q000494:pharmacology*; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D055646:Killer Factors, Yeast; D008222:Lymphokines; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D052899:Pore Forming Cytotoxic Proteins; D011506:Proteins; D054353:Perforin; D004247:DNA; D002118:Calcium